Suzhou Basecare Medical (HKSE:02170) Cash-to-Debt : 3.35 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Suzhou Basecare Medical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Suzhou Basecare Medical's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.35.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Suzhou Basecare Medical could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Suzhou Basecare Medical's Cash-to-Debt or its related term are showing as below:

HKSE:02170' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.73 Med: 4.73 Max: 31.36
Current: 3.35

During the past 6 years, Suzhou Basecare Medical's highest Cash to Debt Ratio was 31.36. The lowest was 1.73. And the median was 4.73.

HKSE:02170's Cash-to-Debt is ranked better than
58.69% of 857 companies
in the Medical Devices & Instruments industry
Industry Median: 1.9 vs HKSE:02170: 3.35

Suzhou Basecare Medical Cash-to-Debt Historical Data

The historical data trend for Suzhou Basecare Medical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Suzhou Basecare Medical Cash-to-Debt Chart

Suzhou Basecare Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1.73

6.11

31.36

17.64

3.35

Suzhou Basecare Medical Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial					31.36	26.46	17.64	4.84	3.35

Competitive Comparison of Suzhou Basecare Medical's Cash-to-Debt

For the Medical Devices subindustry, Suzhou Basecare Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Suzhou Basecare Medical's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Suzhou Basecare Medical's Cash-to-Debt falls into.

Suzhou Basecare Medical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Suzhou Basecare Medical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1031.67	/	(16.61	+	291.745)
	=	3.35

Suzhou Basecare Medical's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1031.67	/	(16.61	+	291.745)
	=	3.35

Suzhou Basecare Medical (HKSE:02170) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Suzhou Basecare Medical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Suzhou Basecare Medical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Basecare Medical (HKSE:02170) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Suzhou Basecare Medical Corp Ltd (HKSE:02170) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

BioBay, No. 218 Xinghu Street, Unit 101, Building A3, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000

Website

https://www.basecare.cn

Suzhou Basecare Medical Corp Ltd is engaged in providing genetic testing solutions for assisted human reproduction. The company generates revenues from Sales of testing kits, followed by Sales of testing devices and instruments. Basecare focuses on the assisted reproductive sector, such as pre-implantation genetic screening and diagnosis, non-invasive prenatal DNA testing, and chromosome abnormalities testing. It generates revenue from China.

Executives

Orbimed Capital Llc	2102 Investment manager
Lake Bleu Prime Healthcare Master Fund Limited	2201 Interest of corporation controlled by you
Orbimed Partners Master Fund Limited	2101 Beneficial owner
Dawn Capital Fund	2101 Beneficial owner
Dawn Capital Limited	2102 Investment manager
Hh Spr-xiv Cy Holdings Limited	2201 Interest of corporation controlled by you
Hh Spr-xiv Hk Holdings Limited	2101 Beneficial owner
Hh Spr-xiv Holdings L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager

Suzhou Basecare Medical (HKSE:02170) Headlines

No Headlines